Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2B6 | P20813 | 1/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.50 |
| ▸ | HTR1A | P08908 | 3/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | SCN1A | P35498 | 1/20 | 0.47 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.47 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2423921 | 0.98 | CYP2B6 (0.55) | CYP2B6CHRM2CHRM1CYP2D6KCNH2 | |
| SCHEMBL8537991 | 0.89 | CYP2B6 (0.49) | CYP2B6CHRM2CHRM1CYP2D6KCNH2 | |
| SCHEMBL25772069 | 0.80 | CYP2B6 (0.55) | CYP2B6CHRM2CHRM1CYP2D6KCNH2 | |
| SCHEMBL27323649 | 0.79 | CYP2B6 (0.55) | CYP2B6CHRM2CHRM1CYP2D6KCNH2 | |
| SCHEMBL10459209 | 0.77 | ALDH1A1 (0.44) | CYP2B6CHRM2LMNACHRM3KDM4E | |
| SCHEMBL2491599 | 0.77 | CYP2B6 (0.63) | CYP2B6CHRM2CHRM1CYP2D6KCNH2 | |
| SCHEMBL19296941 | 0.77 | CYP2B6 (0.63) | CYP2B6CHRM2CHRM1CYP2D6KCNH2 | |
| SCHEMBL6552278 | 0.77 | CYP2B6 (0.62) | CYP2B6CHRM2CHRM1CYP2D6KCNH2 | |
| SCHEMBL27512467 | 0.77 | CYP2B6 (0.52) | CYP2B6CHRM2CHRM1CYP2D6KCNH2 | |
| SCHEMBL11201378 | 0.76 | CYP2B6 (0.52) | CYP2B6CHRM2CHRM1CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399422-A2 | NOVEL CRYSTALLINE FORMS OF 4-[4-[4-(HYDROXYDIPHENYLMETHYL)-1-PIPERIDINYL] -1-HYDROXYBUTYL] -A,A-DIMETHYLBENZENE ACETIC ACID AND ITS HYDROCHLORIDE | Dr. Reddy's Laboratories Ltd. (IN) | 2004-03-24 | — | — | EP | claimed |
| WO-2002102777-A2 | NOVEL CRYSTALLINE FORMS OF 4-[4-[4-(HYDROXYDIPHENYLMETHYL)-1-PIPERINDINYL]-1-HYDROXYBUTYL]-α, α-DIMETHYLBENZENE ACETIC ACID AND ITS HYDROCHLORIDE | DR. REDDY'S LABORATORIES LTD. (IN) | 2002-12-27 | — | — | WO | claimed |
| US-20090264433-A1 | Compounds, Compositions and Methods Comprising Triazine Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-10-22 | — | — | US | disclosed |
| CN-1897930-A | Compositions and methods for treating contracture | ANGIOTECH INT AG (CH) | 2007-01-17 | — | — | CN | disclosed |
| US-20060241303-A1 | Piperidine derivatives and process for their production | AMR TECHNOLOGY, INC. (US) | 2006-10-26 | — | — | US | disclosed |
| CN-1756530-A | Drug delivery from rapid gelling polymer compositions | ANGIOTECH INTERNAT GMBH (CH) | 2006-04-05 | — | — | CN | disclosed |
| CN-1756571-A | Tissue reactive compounds and compositions and uses thereof | ANGIOTECH INTERNAT GMBH (CH) | 2006-04-05 | — | — | CN | disclosed |
| WO-2005011604-A2 | COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH AN ANTIHISTAMINE FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | EPIGENESIS PHARMACEUTICALS LLC (US) | 2005-02-10 | — | — | WO | disclosed |
| US-5777125-A | Process for the preparation of tertiary carbinols containing an amino substituent | GRUPPO LEPETIT SPA (IT) | 1998-07-07 | — | — | US | disclosed |
| US-5750703-A | Piperidine derivatives and process for their production | ALBANY MOLECULAR RESEARCH, INC. (US) | 1998-05-12 | — | — | US | disclosed |
| EP-0508334-B1 | Novel aminophenol derivatives and pharmaceutical compositions thereof | GREEN CROSS CORP (JP) | 1998-01-07 | — | — | EP | disclosed |
| EP-0330875-B1 | Process for the preparation of tertiary carbinols containing an aminic substituent | LEPETIT SPA (IT) | 1995-08-16 | — | — | EP | disclosed |
| US-5308840-A | Antioxidants, antiallergens and antiinflammatory agents | GREEN CROSS CORPORATION (JP) | 1994-05-03 | — | — | US | disclosed |
| EP-0508334-A2 | Novel aminophenol derivatives and pharmaceutical compositions thereof | THE GREEN CROSS CORPORATION (JP) | 1992-10-14 | — | — | EP | disclosed |
| EP-0330875-A2 | Process for the preparation of tertiary carbinols containing an aminic substituent | GRUPPO LEPETIT S.p.A. (IT) | 1989-09-06 | — | — | EP | disclosed |
| EP-0181793-B1 | PIPERIDINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTICAL APPLICATION | SYNTHELABO (FR) | 1988-07-27 | — | — | EP | disclosed |
| EP-0181793-A1 | Piperidine derivatives, their preparation and their therapeutical application | SYNTHELABO (FR) | 1986-05-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241303-A1 | Piperidine derivatives and process for their production | HRH4, DRD4, H1-4 | CYP2B6 185/4885CHRM2 510/4885CHRM1 235/4885 |
| US-20090264433-A1 | Compounds, Compositions and Methods Comprising Triazine Derivatives | CFTR, PKD1, PKD2 | CYP2B6 3114/4885CHRM2 3202/4885CHRM1 3807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.